Tag:
Tim Anderson
Latest Headlines
Latest Headlines
Analyst gloomy on Merck trends
An influential pharma analyst downgraded Merck shares, saying they've hit their price ceiling. Why? The reasons can be summed up in four drugs: Singulair, Gardasil, taranabant, and Vytorin. Sanford
Rumor mill: BMS positioning itself for sale
Speculation that Bristol-Myers Squibb might be a takeover target -- that's old news. Informed speculation based on certain strategic moves BMS has made recently -- worth passing on. Tim Anderson, the
